Xenetic Biosciences FY 2022 net loss $6.6M; cash $13.1M; DNase platform advances toward Phase 1

Xenetic Biosciences, Inc.

Net loss for FY 2022 was approximately $6.6 million; R&D expenses rose 50.8% to $4.8M.
Cash at year-end totaled $13.1 million, expected to fund operations and pipeline development.
Royalty payments from Takeda sublicense were ~$1.7M, up 47.1% YoY.
DNase oncology platform progressing towards first-in-human study combined with checkpoint inhibitors or chemo.
Appointed oncology and NETs experts Allan Tsung, MD and Jonathan Spicer, MD, PhD to Scientific Advisory Board.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Xenetic Biosciences, Inc. reported the full year 2022 results: net income Net loss for the year ended December 31, 2022 was approximately $6.6 million..

Period: the full year 2022
Net income: Net loss for the year ended December 31, 2022 was approximately $6.6 million.
Result: reported results

Exact text from the filing

On March 23, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the year ended December 31, 2022 and providing a corporate update.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-001681

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.